Locations:
Search IconSearch

Elegant Procedure Preserves Teen’s Vision and Self-Confidence

Growing tumor sparks concern for melanoma

Mystery Eye

A 16-year-old girl presented to Cleveland Clinic with a growing pigmented lesion of the left iris that was initially noted 5 years earlier. The girl’s visual acuity was 20/20 in the left eye, but her examination was remarkable for a 2- x 1.2- x 1-mm pigmented lesion in the 5 o’clock position with pupillary margin involvement.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The ongoing growth of the lesion was confirmed by comparing the appearance of the affected eye with earlier photographs of the patient.

Initial examination reveals a pigmented lesion with pupillary margin involvement.

“The examination findings and changing appearance of the nevus were concerning for iris melanoma, a diagnosis that must be confirmed by biopsy,” explains Arun Singh, MD, Director of the Department of Ophthalmic Oncology in the Cole Eye Institute. “In this case, our principal challenges included removing the tumor completely and with clear margins, protecting the patient’s vision and appearance, reconstructing the pupil and restoring ocular function.”

Following a discussion of treatment options, the patient agreed to undergo an excisional biopsy of the lesion. Using a minimally invasive approach, Dr. Singh performed an iridectomy and pupilloplasty to reconstruct the delicate tissue of the iris and recreate an appropriately sized pupil.

Novel surgical approach minimizes complications

Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defects.

Approximately 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, this approach involves multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.

Advertisement

The next step, pupilloplasty, restores the iris to a near-normal shape using a suturing slip-knot technique. This restoration of the iris not only repairs the cosmetic defect but also helps prevent photophobia.

“The larger incisions required by conventional techniques led to a number of risks that can now be avoided,” says Dr. Singh. “This minimally invasive approach results in faster healing and much better functional and cosmetic outcomes.”

Biopsy reveals benign growth

Histopathology demonstrated a densely pigmented lesion with a fair amount of cytoplasm and no mitotic activity. These findings were consistent with melanocytoma, a benign, deeply pigmented tumor that most commonly arises on or adjacent to the optic nerve head. Such growths most commonly arise on or adjacent to the optic nerve head; however, they often appear on the iris of younger patients.

“We always approach these kinds of cases with caution because the goal is to remove the entire tumor without compromising the patient’s vision,” explains Dr. Singh. “In this particular case, the stakes were somewhat elevated because the patient was so young, and our ability to restore the external appearance of the eye was one of her chief concerns.”

At one-week follow-up, the patient’s eye was healing well, and her visual acuity was 20/20 in the left eye.

Stitches are still visible at one-week follow-up, but the patient’s eye appeared to be healing properly.

At three month follow-up, the patient’s visual acuity and ocular pressures were stable, and her eye had a normal cosmetic appearance.

Advertisement

Virtually no signs of the tumor were visible three months after the procedure.

“If this patient would have come to us two decades ago, our best option would be to simply watch the lesion while hoping to avoid a big surgery,” says Dr. Singh. “Thanks to the development of these minimally invasive techniques, we were able to treat her safely and with great success.”

Advertisement

Related Articles

Singh-image-690-x-380
August 26, 2014/Cancer/Ophthalmic Oncology
Importance of Optical Coherence Tomography Grows

Report details imaging benefit, limitations

690×380-Eye-Tumor
Small Incision Resection of Iris Melanoma

Case study of a 17-year-old with an asymptomatic iris lesion

Cancer patient being hugged by a loved one
September 4, 2024/Cancer/Blood Cancers
Study Finds Immunotherapy Increases Three-Year Survival in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone

Doctor and team talking to patient in hospital bed
August 30, 2024/Cancer/Patient Support
New Cellular and Immunotherapy Service Provides Patients with Standard of Care and Clinical Trial Opportunities for Novel Therapies

Patients receive specialized inpatient and outpatient care for cellular, gene and immune cell-engaging therapies

Before and after scan
August 28, 2024/Cancer/Research
Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research
Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research
Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Dr. Chirag Shah and colleague
August 12, 2024/Cancer/Research
DCISionRT Decision Score Predicts the Need of Radiation Therapy for Treating Ductal Carcinoma in Situ

Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy

Ad